KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the conference on Tuesday, Jan. 10, at 3:00 p.m. PST.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA
Biopharmaceuticals, Inc. is a privately held, clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel prescription products for the aesthetic
market. KYTHERA's lead clinical program, ATX-101, is focused on the
reduction of submental (under the chin) fat. The company also has active
research programs with focused interest in hair and fat biology,
pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
Contacts:
KYTHERA Biopharmaceuticals, Inc.
Investor Contact:
Heather
Rowe, 818-587-4559
hrowe@kytherabiopharma.com
or
Media
Contact:
Erica Bazerkanian, 805-300-9289
ebazerkanian@kytherabiopharma.com
